Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative sacituzumab govitecan + zimberelimab + domvanalimab in cisplatin-ineligible muscle-invasive bladder cancer
2023-504420-26-00Phase 2Authorised
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan, zimberelimab and domvanalimab in bladder cancer and transitional cell carcinoma (TCC), sponsored by Fundación para el Progreso de la Oncología en Cantabria. Primary endpoint: Pathologic complete response rate. Planned start Jan 2025; status: authorised.
02
Drugs
sacituzumab govitecanzimberelimabdomvanalimab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-504420-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504420-26-00.